FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

ashington, I	D.C.	20549	
--------------	------	-------	--

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Alleva Lawrence M			3.	Issuer Name and Ticker or Trading Symbol     Mersana Therapeutics, Inc. [ MRSN ]     Joate of Earliest Transaction (Month/Day/Year)					(Che	ck all applic  Director  Officer	able)	erson(s) to Issu 10% Ov Other (s	vner		
(Last) (First) (Middle)  C/O MERSANA THERAPEUTICS, INC.  840 MEMORIAL DRIVE				01/02/2024  4. If Amendment, Date of Original Filed (Month/Day/Year)					below) below)  6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	IDGE M	ΙA	02139			401.5.4		<del>-</del>			2		led by More th	eporting Person	
(City)	(S	tate)	(Zip)		Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										
		Tak	ole I - Non-D	erivativ	e Se	curities	Acc	uired, Di	sposed o	f, or Ben	eficiall	y Owned			
Date			Transaction te onth/Day/Y	Execution Date,		3. Transaction Code (Instr. 3) 5) 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5)				5. Amour Securitie Beneficia Owned F	s Form ally (D) or ollowing (I) (In	orm: Direct ) or Indirect (Instr. 4)	7. Nature of ndirect Beneficial Ownership		
							Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	or Exercise (Month/Day/Year) if any		Execution Date,	4. Transaction Code (Instr. 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Stock Option (right to buy)	\$2.27	01/02/2024		A		7,763 <sup>(1)</sup>		(2)	01/01/2034	Common Stock	7,763	\$0	7,763	D	

## **Explanation of Responses:**

1. This stock option was granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of stock options rather than cash. The options were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as amended, in lieu of retainer fees of \$14,750 for the quarter ended December 31, 2023.

2. Fully vested as of the date of grant.

/s/ Alejandra Carvajal, 01/04/2024 Attorney-in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.